Australia markets closed

Xeris Biopharma Holdings, Inc. (XERS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.2100+0.1700 (+8.33%)
At close: 04:00PM EDT
2.2100 0.00 (0.00%)
After hours: 07:52PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.0400
Open2.1300
Bid2.1600 x 1000
Ask2.2600 x 500
Day's range2.1100 - 2.2799
52-week range1.4400 - 3.2600
Volume3,193,526
Avg. volume2,376,073
Market cap310.401M
Beta (5Y monthly)1.21
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events

    CHICAGO, March 06, 2024--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the fourth quarter and full-year ended December 31, 2023 and recent events.

  • Business Wire

    Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital

    CHICAGO, March 06, 2024--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced it has entered into an amended and restated senior secured term loan agreement ("debt facility") with funds managed by Hayfin Capital Management LLP ("Hayfin") to provide Xeris $200.0 million of capital at close and the ability to draw down anoth

  • Business Wire

    Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024

    CHICAGO, February 28, 2024--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its fourth quarter and full year 2023 financial results before the open of the U.S. financial markets on Wednesday, March 6, 2024. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that